TAR 200

Drug Profile

TAR 200

Alternative Names: Gemcitabine-releasing intravesical system - TARIS; GemRIS™; TAR-200

Latest Information Update: 18 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AstraZeneca; TARIS Biomedical
  • Developer TARIS Biomedical
  • Class Antineoplastics; Deoxyribonucleosides; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action Antimetabolites; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Bladder cancer

Most Recent Events

  • 16 Apr 2018 Pharmacodynamics data from a preclinical study in Bladder cancer released by TARIS
  • 03 Apr 2018 TAR 200 receives Fast Track designation for Bladder cancer [Intravesicular,Controlled release] in USA
  • 21 Dec 2017 TARIS Biomedical and Bristol-Myers Squibb enter into a clinical trial collaboration agreement for muscle invasive Bladder cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top